<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656769</url>
  </required_header>
  <id_info>
    <org_study_id>ANNULAR</org_study_id>
    <nct_id>NCT04656769</nct_id>
  </id_info>
  <brief_title>Analgesia aNd caNcer recUrrence Lung cAncer Resection</brief_title>
  <official_title>Impact of Analgesia on Cancer Recurrence and Mortality Within Five Years After Stage I Non-Small Cell Lung Cancer Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The choice of analgesia after cancer surgery may play a role in the onset of recurrence,&#xD;
      particularly opioids seem to play a role in the immune system by promoting cancer cell&#xD;
      proliferation and migration. Based on this consideration, our aim was to assess the impact of&#xD;
      perioperative analgesia's choice on cancer recurrence after curative surgery for Stage I&#xD;
      Non-Small Cell Lung Cancer. The investigators retrospectively reviewed the records of&#xD;
      patients who underwent lung resection for Stage I NSCLC between January 2005 and December&#xD;
      2012. Patients received analgesia either by peridural (PERI group) or, in case of patient&#xD;
      refusal or failure in catheter positioning, intravenous analgesia with opioids (EV group).&#xD;
      Follow-up was concluded in August 2019. The five-year cumulative incidence of recurrence and&#xD;
      the overall survival were evaluated and adjusted with a propensity score matching&#xD;
      methodology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Actual">November 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative incidence of recurrence and the overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">382</enrollment>
  <condition>Recurrence Tumor</condition>
  <condition>Opioid Use, Unspecified</condition>
  <condition>Analgesia</condition>
  <condition>Thoracic Surgery</condition>
  <arm_group>
    <arm_group_label>PERI group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>EV group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peridural analgesia</intervention_name>
    <description>We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.</description>
    <arm_group_label>PERI group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent lung resection for Stage I NSCLC between January 2005 and December&#xD;
        2012&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 yrs&#xD;
&#xD;
          -  Patients who underwent lung resection for Stage I NSCLC between January 2005 and&#xD;
             December 2012&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&lt;18aa&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Day hospital patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Brazzi, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Torino</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giulio L Rosboch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Città della salute e della Scienza di Torino</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilaria De Domenici, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Torino</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edoardo Ceraolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Città della salute e della Scienza di Torino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turin, Italy</investigator_affiliation>
    <investigator_full_name>Luca Brazzi</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Recurrence tumor</keyword>
  <keyword>Opioid use</keyword>
  <keyword>Analgesia</keyword>
  <keyword>thoracic surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

